Corrigendum to “Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis” [Pharmaceut. Sci. Adv. 2 (2024), 100030]
Pharmaceutical Science Advances · 2026-12 · 4 · 100144
DOI: 10.1016/j.pscia.2026.100144 ↗Kurz gefasst
Korrektur in der Zeitschrift Pharmaceutical Science Advances, 2026-12. Verfasst von Dongyang Gao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
- Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
- Shenzhen Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Shenzhen, 518033, China.
Zitieren
APA
Gao, D., Gao, W., Zhai, Z., & Zhu, W. (2026). Corrigendum to “Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis” [Pharmaceut. Sci. Adv. 2 (2024), 100030]. Pharmaceutical Science Advances, 4, 100144. https://doi.org/10.1016/j.pscia.2026.100144
Vancouver
Gao D, Gao W, Zhai Z, Zhu W. Corrigendum to “Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis” [Pharmaceut. Sci. Adv. 2 (2024), 100030]. Pharmaceutical Science Advances. 2026;4:100144. doi:10.1016/j.pscia.2026.100144
BibTeX
@article{Gao2026,
author = {Gao, Dongyang and Gao, Wenli and Zhai, Zhiguang and Zhu, Wenxiang},
title = {Corrigendum to “Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis” [Pharmaceut. Sci. Adv. 2 (2024), 100030]},
journal = {Pharmaceutical Science Advances},
year = {2026},
volume = {4},
pages = {100144},
doi = {10.1016/j.pscia.2026.100144}
}
EUVIMED